TickerFacts.

RxSight, Inc. (RXST): R&D Expense

Annual figures by period end, from SEC filings.

$38.55M
Year ended 2025-12-31
$36.67M
Trailing 12 months to 2026-06-30
+14.1%
3-year compound annual growth
+11.9%
5-year compound annual growth
2020-12-31: $21.93M2021-12-31: $24.50M2022-12-31: $25.98M2023-12-31: $29.05M2024-12-31: $34.37M2025-12-31: $38.55M$38.55M
2020-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$38.55M+12.2%2026-02-25, From 2025-01-01
2024-12-31$34.37M+18.3%2026-02-25, From 2024-01-01
2023-12-31$29.05M+11.8%2026-02-25, From 2023-01-01
2022-12-31$25.98M+6.0%2025-02-25, From 2022-01-01
2021-12-31$24.50M+11.7%2023-03-06, From 2021-01-01
2020-12-31$21.93Mn/a2022-03-08, From 2020-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Ophthalmic Goods), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
RxSight, Inc. (RXST)2025-12-31$38.55M+12.2%
Staar Surgical Co (STAA)2026-01-02$40.05M-11.6%
Cooper Companies, Inc. (COO)2025-10-31$172.20M+11.0%
Bausch & Lomb Corp (BLCO)2025-12-31$371.00M+8.2%
Innovative Eyewear Inc (LUCYW)2025-12-31$725.4K-11.5%

Compare RXST, STAA, COO, BLCO side by side · Screen every company in Ophthalmic Goods ↗